drugset / Trial / NCT05329792
L19IL2/L19TNF in Skin Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2024-06
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darleukin | Protein / enzyme biologic | — | Other |
| Subject | Onfekafusp alfa | Protein / enzyme biologic | — | Other |